Table 2: Description of Direct Comparison Studies Included in Clinical Example and Risk of Withdrawing Due to Adverse Events
| Study |
Treatment |
Number of Subjects
who
Withdrew Due to Adverse events |
Number of Subjects
in Treatment Arm |
Risk of Withdrawal
Due to Adverse Events |
Risk Difference
(95% Confidence
Interval) |
| 1 [5] |
Gabapentin |
15 |
115 |
13.00% |
-6.7% (-14% to 0.9%) |
| 1 [5] |
Placebo |
7 |
111 |
6.31% |
| 2 [6] |
Nortriptyline |
5 |
38 |
13.16% |
-5.66% (-19% to 7%) |
| 2 [6] |
Placebo |
3 |
40 |
7.50% |
| 3 [7] |
Nortriptyline |
1 |
38 |
2.63% |
2.63% (-2.4% to 7%) |
| 3 [7] |
Gabapentin |
0 |
38 |
0.00% |